Original StudySurvival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study
Introduction
An increasing number of patients have been diagnosed with colorectal cancer (CRC) in the past few decades in China.1 Approximately 50% of the CRC patients will develop metastatic disease,2 among which 29% will have initial lung metastasis (LM).3 However, the characteristics of LM have not been well studied.4, 5
Although not based on well-designed randomized clinical trials, radical lung metastasectomy is the recommended treatment approach for resectable LM with good prognosis and no extrapulmonary disease.6, 7 Radiofrequency ablation and stereotactic body radiotherapy are alternative treatments in cases that are unsuitable for surgery.8, 9 Among the initial LM population, 10% were suitable for radical therapy, while others were only eligible for palliative pharmacotherapy with or without local therapy.3
Pharmacotherapy is frequently used in clinical practice, but few data are available regarding the efficacy of chemotherapy, with or without targeted therapy. Some early studies suggested a better response and longer survival with the FOLFOX regimen (5-fluorouracil/leucovorin plus oxaliplatin) compared to FOLFIRI (5-fluorouracil/leucovorin plus irinotecan), but the differences were not significant.10, 11 These studies were of great importance, but they failed to provide definitive recommendations on pharmacotherapy for LM. Moreover, the additional role of local therapy in the palliative setting has not been investigated.
We retrospectively investigated the characteristics of CRC patients presenting with initial LM, clarified the impact of palliative local treatments on survival, and explored the efficacy of chemotherapy with or without targeted agents.
Section snippets
Patients
A total of 2676 medical records of CRC patients who were treated in the Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, from January 1, 1996, through April 1, 2017, were reviewed. Of these, 2233 metastatic cases were identified, and among these, 731 patients were diagnosed with LM on the basis of chest computed tomographic scan or positron emission tomography–computed tomographic scan. LM was confirmed pathologically if necessary. After excluding the
Characteristics of LM
Overall, the number of patients diagnosed as having metastatic CRC (mCRC) has increased steadily over the past 20 years (Supplemental Figure 1 in the online version). Among the 684 patients included in the analysis of LM characteristics, 242 patients were identified as having isolated initial LM, 302 as having nonisolated initial LM, and 140 as having non–initial LM. The incidence of initial LM was higher in metastatic rectal cancer (32.5%, 304/934) than in colon cancer (18.5%, 240/1299).
Discussion
To our knowledge, no previous studies have investigated the epidemiology of LM in CRC patients in China. We found that there was a similar incidence of initial LM (24.4%) compared to a study in Italy (29.2%), and that the proportion of isolated LM among patients with initial LM was higher (46.4%, 140/302, vs. 37.7%, 154/409) in the Chinese population.3 Taking the increasing number of CRC patients1 and CRC-LM patients4 into consideration, LM has become a common diagnosis that many oncologists
Conclusion
The present study investigated the characteristics of LM in CRC. Palliative local treatment of LM was associated with longer OS than pharmacotherapy alone. Nonintensive first-line treatment with a single-agent fluoropyrimidine could be used in patients with good prognosis to improve quality of life without impairing survival. These encouraging results should be further investigated in prospective randomized clinical trials. Further, molecular profiling of CRC might provide new insights into the
Disclosure
The authors have stated that they have no conflict of interest.
Acknowledgment
We thank LetPub (http://www.letpub.com/) for English-language editorial help.
References (33)
- et al.
ESMO Guidelines Working Group, Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
Ann Oncol
(2014) - et al.
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Ann Oncol
(2016) - et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eur J Cancer
(2009) - et al.
Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients
Cancer Cell
(2016) - et al.
Cancer statistics in China, 2015
CA Cancer J Clin
(2016) - et al.
The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study
Oncologist
(2012) - et al.
Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study
Gut
(2010) - et al.
Incidence and predictive factors for pulmonary metastases after curative resection of colon cancer
Ann Surg Oncol
(2013) - et al.
Colorectal cancer and thoracic surgeons: close encounters of the third kind
Exp Rev Anticancer Ther
(2012) - et al.
Management of resectable colorectal lung metastases
Clin Exp Metastasis
(2016)